AANA journal
-
Randomized Controlled Trial
The effect of transdermal scopolamine on the incidence and severity of postoperative nausea and vomiting in a group of high-risk patients given prophylactic intravenous ondansetron.
Specific risk factors place patients at greater risk for postoperative nausea and vomiting (PONV). Routinely, these patients are treated prophylactically with intravenous (IV) ondansetron or transdermal (TD) scopolamine. No study has examined what effect using a combination of these prophylactic treatments would have on the incidence of PONV in a group of high-risk patients. ⋯ No difference in demographics or the incidence of side effects was noted between groups. Patients in the scopolamine group had a lower incidence of PONV (P = .043), longer time to first reported nausea (P = .044), longer time to first episode of emesis (P = .031), and decreased supplemental antiemetic requirements (P = .016) compared with the placebo group. Based on this study, we recommend using a combination of TD scopolamine and IV ondansetron to prevent PONV in patients identified as high risk for PONV.
-
Comparative Study
Pollution of ambient air by volatile anesthetics: a comparison of 4 anesthetic management techniques.
Long-term exposure to waste anesthetic gas (WAG) may lead to health problems. The purpose of this study was to compare WAG concentrations resulting from 4 combinations of fresh gas flow (FGF) and vaporizer settings during a simulated intravenous induction in which the anesthetic is deepened using a volatile anesthetic delivered via mask ventilation before intubation. By using a lung model, WAG was sampled 3 times each using 4 combinations and 3 volatile anesthetics: 3% sevoflurane, 2% isoflurane, and 6% desflurane. ⋯ Regardless of the agent, only the FGF on/vaporizer on combination at 60 seconds resulted in a statistically greater WAG level (P < .005). The results support using 3 of the 4 combinations examined when mask ventilation with a volatile agent accompanies intravenous induction. Future studies should examine other methods of controlling WAG levels and use time-weighted averages to help address clinical significance.
-
Perioperative beta blockade has been proven to significantly reduce the incidence of myocardial ischemia and myocardial infarction and of long-term overall mortality related to cardiac events after various surgeries in patients at intermediate or high risk for such events. The major physiologic effects of beta blockers result in a positive balance of myocardial oxygen supply and demand. Although the optimal time frame for initiation of treatment is not clear from the available data, it has been shown that beta blocker therapy is effective when started at least 1 week before the scheduled surgery and continued throughout the postoperative period. The current recommendations for perioperative beta blockade for patients at intermediate and high risk for a perioperative cardiac event are to use a beta1 blocking agent, begin therapy several weeks before a planned operation, titrate the dose to achieve a heart rate of 60 to 70 beats per minute, and taper the dose of the beta blocker after the postoperative period.